

Tilray Inc

12:00 14 Aug 2019

Buds & Duds: Cannabis stocks lag as Tilray shares slump on wider-than-expected 2Q loss

Cannabis stocks slipped on Wednesday with broad-based losses across North American markets and a string of disappointing earnings results.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, dropped 3.8% at 206.1 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF sank 4.4% to C\$16.70, while the OTCQX Cannabis Index dropped 4% to 701.8 points.

Duds

The duds led the way on Wednesday, with the majority of cannabis stocks lagging.

Tilray Inc (NASDAQ:TLRY) shares sank 10.5% at US\$41.18 in New York after reporting wider-than-expected losses in its fiscal second quarter, despite seeing a bump in sales, on the back of acquisitions that helped results.

The cannabis cultivation company reported revenue of US\$45.9 million, as compared to US\$9.7 million in the year-ago period, and beating the US\$40.35 million expected by analysts. The firm pointed to its acquisition of Manitoba Harvest, recreational legalization in Canada, and growth in Europe's medical marijuana market as reasons for the rise.

Net loss for the quarter was US\$35.1 million or \$0.36 per share compared to a loss of US\$12.8 million or \$0.17 per share in the same period a year ago. Tilray said the widening loss was due to an increase in operating expenses, interest expenses, acquisitions and the expansion of its international operations.

The firm noted average net selling prices including taxes fell to US\$4.61 per gram, down 28% from the year earlier.

Also lagging Wednesday was US multi-state cannabis operator Cresco Labs Inc (OTCMKTS:CRLBF) (CSE:CL), which was down 4.2% at C\$11.38 in Toronto, off 5.5% at US\$8.50 in New York.

Yesterday, the firm announced a listing on the Frankfurt Stock Exchange, under the symbol 6CQ.

Also dropping was Sunniva Inc (CSE:SNN) (OTCMKTS:SNNVF), which saw its shares slide by 42.4% at C\$1.17 in Canadian trading, off 43.2% at US\$0.88 in New York.

The firm, which operates in Canada and California, announced delays of several months at its Cathedral City, California facility. The firm noted the expected date for phase one of its 325,000 sq/ft Sunniva California campus is now anticipated to be early 2020.


Buds

That said, a number of stocks outperformed Wednesday.

Price: \$28.19

Market Cap: \$2.75 billion

1 Year Share Price Graph



September 2018 March 2019 September 2019

Share Information

Code: TLRY

Listing: NASDAQ

52 week High Low
178.85 25.17

Sector: Cannabis

Website: www.tilray.com

Company Synopsis:

Tilray Inc is a vertically-integrated and federally-licensed cannabis cultivator, processor and distributor based in British Columbia.

action@proactiveinvestors.com

Biome Grow Inc (CSE:BIO) (OTCMKTS:BIOIF) shares were on the rise after the firm announced it is bringing its cannabis products to Manitoba.

Shares of Biome Grow were up 4% at C\$0.39 in Toronto, up 1.4% at US\$0.28 in New York.

The company won a license for the retail sale of cannabis in the province and plans to distribute its select dried flower and pre-rolls to retailers from its wholly-owned Nova Scotia cultivation facility, Highland Grow.

"We are happy that our high quality, premium flower and pre-rolls have which have proven very popular with discerning consumers in Atlantic Canada and Saskatchewan will now be available to the 1.4 million people of 'Friendly Manitoba'," said Biome Grow CEO Khurram Malik.

READ: Biome Grow wins license to distribute cannabis in 'Friendly Manitoba'

Also gaining Wednesday was TILT Holdings Inc (CSE:TILT) (OTCMKTS:SVVTF), which was up 1.3% at C\$0.81 in Toronto. The firm is expecting its latest round of financial results at the end of August.

TILT is an infrastructure and technology platform for the legalized cannabis industry and services around 1,000 dispensaries across the US and Canada

Contact Katie Lewis at katie@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.